After Treatment: Integration and Relapse

Treatment sells the experience. What decides the outcome happens after everyone has gone home, and it is the least documented part of the whole subject.

The danger nobody puts in the brochure

Opioid tolerance falls during abstinence. That is the entire mechanism and its consequence is severe: the amount someone used routinely before treatment can be a fatal overdose afterwards.

This is why the timing of a relapse matters more than the fact of one. Someone who returns to use two weeks after treatment is not returning to where they started. They are returning to an old dose with a new body.

What the numbers actually show

The largest follow-up asked 88 people treated in Mexico what had happened.

Thirty percent of participants reported never using opioids again following ibogaine treatment. Although 70% of the total sample reported a relapse following treatment, 48% reported decreased use from pretreatment levels and an additional 11% eventually achieved abstinence.

Both halves of that are real and this site publishes both. Thirty per cent never using again is a striking figure. Seventy per cent relapsing is the same study.

Three of the five authors were affiliated with the clinic where participants were treated, and the conflict statement says only that all financial interests have been reported. It is also a retrospective survey of people the clinic could still reach, which systematically excludes those who went worst.

The shape of the curve matters as much as the numbers. In a prospective cohort of 30 people, the improvement in drug use was maximal at one month, then sustained from three to twelve months at levels that never regained the one-month effect. Half reported no opioid use in the previous 30 days at one month; by twelve months it was seven of thirty.

Why there is no success rate sets out why none of these figures can be turned into one.

The follow-up itself collapses

This is a limitation worth naming, because it shapes every number above.

The two largest and most-cited studies stop at one month. Nobody has published what happens to an ibogaine cohort at two years, and nobody has published what happens to the people who relapsed. They are counted once and then disappear from the literature.

What the research says helps

There is one real finding here and it points away from the experience.

A mixed-method study of 73 people compared those who did well with those who did not, and named what was missing. Its conclusion: notable challenges included psychological and health-related difficulties during treatment and challenges with post-treatment integration, and the findings highlight possible post-treatment needs, meaning more integration and aftercare resources.

A New Zealand qualitative study of ten people reached the same place: preparation, medical screening and post-treatment psychosocial support were critical to positive outcomes.

And the veteran study records something honest about the month afterwards. Several participants experienced a recurrence of notable psychiatric symptoms between the immediate post-treatment assessment and the one-month follow-up, and in at least two cases substantial psychosocial stressors on return home appeared to play a role.

That last detail is the whole argument for aftercare. The effect does not decay in a laboratory. It decays when someone goes back to the life they left.

The physical weeks

Less dramatic and worth planning for.

The metabolite has a half-life of 28 to 49 hours, so it is present for days after discharge. Coordination takes time to settle: in the hospital series all fourteen patients could not walk unsupported, most recovered within 24 hours and five took a day longer. Sleep is disturbed, and the animal work shows suppression of REM sleep outlasting the drug’s other effects.

You will usually be flying home inside this window. What a treatment involves covers why the residential stay ends before the drug does.

What to arrange before you go

The pattern in the research is that people organise the treatment in detail and the aftermath not at all.

• Who you will speak to in week one, week four and month three, and whether it is included in what you paid.
• What your plan is if you relapse, written down beforehand, including that your tolerance will be lower.
• Whether naloxone is available to you and whoever you live with.
• Who is managing the medications you stopped, and when they resume.
• What happens if the psychiatric symptoms come back, which the veteran study records happening within the first month.

When ibogaine doesn’t work is the page for the outcome nobody plans for, and it is the more likely one.